Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial (vol 6, pg 370, 2018)

被引：0
|
作者：
Ludvik, B.
Frias, J. P.
Tinahones, F. J.
机构：
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2018年 / 6卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E5 / E5
页数：1
相关论文
共 50 条
  • [1] Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
    Ludvik, Bernhard
    Frias, Juan P.
    Tinahones, Francisco J.
    Wainstein, Julio
    Jiang, Honghua
    Robertson, Kenneth E.
    Garcia-Perez, Luis-Emilio
    Woodward, D. Bradley
    Milicevic, Zvonko
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (05): : 370 - 381
  • [2] Liraglutide as add-on to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes: a 26-week, randomised, double-blind, placebo-controlled trial
    Rea, R.
    Blonde, L.
    Belousova, L.
    Fainberg, U.
    Garcia-Hernandez, P. A.
    Jain, S. M.
    Kaltoft, M. S.
    Mosenzon, O.
    Nafach, J.
    Palle, M. S.
    [J]. DIABETOLOGIA, 2019, 62 : S371 - S372
  • [3] Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
    Haering, Hans-Ulrich
    Merker, Ludwig
    Seewaldt-Becker, Elke
    Weimer, Marc
    Meinicke, Thomas
    Broedl, Uli C.
    Woerle, Hans J.
    [J]. DIABETES CARE, 2014, 37 (06) : 1650 - 1659
  • [4] Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes A 24-week, randomized, double-blind, placebo-controlled trial
    Haering, Hans-Ulrich
    Merker, Ludwig
    Seewaldt-Becker, Elke
    Weimer, Marc
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES CARE, 2013, 36 (11) : 3396 - 3404
  • [5] A randomised, double-blind, placebo-controlled, 39 week trial of ITCA 650 as add-on therapy in type 2 diabetes
    Baron, M. A.
    Buse, J.
    Azeem, R.
    Kjems, L.
    Rosenstock, J.
    [J]. DIABETOLOGIA, 2015, 58 : S55 - S55
  • [6] Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial
    Heo, Ji Hye
    Han, Kyung Ah
    Hong, Jun Hwa
    Seo, Hyun-Ae
    Hong, Eun-Gyoung
    Yu, Jae Myung
    Jung, Hye Seung
    Cha, Bong-Soo
    [J]. DIABETES & METABOLISM JOURNAL, 2024, 48 (05)
  • [7] Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
    Clifford J Bailey
    Jorge L Gross
    Delphine Hennicken
    Nayyar Iqbal
    Traci A Mansfield
    James F List
    [J]. BMC Medicine, 11
  • [8] Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
    Bailey, Clifford J.
    Gross, Jorge L.
    Hennicken, Delphine
    Iqbal, Nayyar
    Mansfield, Traci A.
    List, James F.
    [J]. BMC MEDICINE, 2013, 11
  • [9] Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial
    Softeland, Eirik
    Meier, Juris J.
    Vangen, Bente
    Toorawa, Robert
    Maldonado-Lutomirsky, Mario
    Broedl, Uli C.
    [J]. DIABETES CARE, 2017, 40 (02) : 201 - 209
  • [10] Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial
    Kadowaki, Takashi
    Inagaki, Nobuya
    Kondo, Kazuoki
    Nishimura, Kenichi
    Kaneko, Genki
    Maruyama, Nobuko
    Nakanishi, Nobuhiro
    Iijima, Hiroaki
    Watanabe, Yumi
    Gouda, Maki
    [J]. DIABETES OBESITY & METABOLISM, 2017, 19 (06): : 874 - 882
12345